RecruitingOsteoarthritis, KneeDiabetic Neuropathic PainChronic Low-back Pain

A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

Eligible age

18+ yrs

Accepts

All genders

Locations

24 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.

Sponsor: Eli Lilly and Company

You may qualify if…

✓ have a visual analog scale (VAS) pain value \>40 and \<95 at screening and prerandomization screening.
✓ have a history of daily pain for at least 12 weeks based on participant report or medical history
✓ have a value of ≤30 on the pain catastrophizing scale
✓ have a body mass index \<40 kilogram/square meter (kg/m²) (inclusive)
✓ are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.
✓ are willing to discontinue all medications taken for chronic pain conditions, except rescue medication for the duration of the study

You may not qualify if…

✕ have second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia
✕ have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques)
✕ have surgery planned during the study for any reason, related or not to the disease state under evaluation.
✕ have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.
✕ have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.
✕ have fibromyalgia
✕ have substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)
✕ have any clinically important abnormality at screening, as determined by investigator, in physical or neurological examination, vital signs, electrocardiogram (ECG), or clinical laboratory test results that could be detrimental to the participant or could compromise the study.